Literature DB >> 25397587

Safety, Feasibility, and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer: A Retrospective Study.

Orhan Onder Eren1, Mehmet Akif Ozturk, Ozlem Uysal Sonmez, Basak Oyan.   

Abstract

Gastric cancer is still one of the cancers with highest mortality. Most patients present with advanced-stage disease. Palliative chemotherapy is usually the only treatment option for patients with advanced gastric cancer (AGC). Maintenance chemotherapy is an evolving concept in medical oncology. Maintenance chemotherapy can be administered with the same drug(s) in the initial regimen or with an alternative agent. In this article, we report our experience with capecitabine as a maintenance agent for patients with AGC. No treatment-related death was observed due to use of capecitabine. Median progression-free survival was 10.4 months, and median overall survival was 19.7 months. Activity and toxicity profile of capecitabine seems favorable as a maintenance agent in AGC. We believe that capecitabine deserves further trials as a maintenance agent for patients with AGC.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 25397587     DOI： 10.1097/MJT.0000000000000156

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


  4 in total

Review 1.  Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.

Authors:  Petros Grivas; Bradley J Monk; Daniel Petrylak; Martin Reck; Grace Foley; Silke Guenther; Dan Hennessy; Constantin Makris; Markus Moehler
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

2.  Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.

Authors:  A Viúdez; A Carmona-Bayonas; J Gallego; A Lacalle; R Hernández; J M Cano; I Macías; A Custodio; E Martínez de Castro; A Sánchez; L Iglesia; P Reguera; L Visa; A Azkarate; M Sánchez-Cánovas; M Mangas; M L Limón; A Martínez-Torrón; E Asensio; A Ramchandani; A Martín-Carnicero; A Hurtado; P Cerdà; M Garrido; R Sánchez-Bayonas; R Serrano; P Jiménez-Fonseca
Journal:  Clin Transl Oncol       Date:  2019-08-05       Impact factor: 3.405

3.  Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Authors:  Hyun Cheol Chung; Hendrik-Tobias Arkenau; Jeeyun Lee; Sun Young Rha; Do-Youn Oh; Lucjan Wyrwicz; Yoon-Koo Kang; Keun-Wook Lee; Jeffrey R Infante; Sung Sook Lee; Margaret Kemeny; Ulrich Keilholz; Bohuslav Melichar; Alain Mita; Ruth Plummer; Denis Smith; Arnold B Gelb; Huiling Xiong; Janet Hong; Vikram Chand; Howard Safran
Journal:  J Immunother Cancer       Date:  2019-02-04       Impact factor: 13.751

4.  Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.

Authors:  Markus Moehler; Mikhail Dvorkin; Narikazu Boku; Mustafa Özgüroğlu; Min-Hee Ryu; Alina S Muntean; Sara Lonardi; Marina Nechaeva; Arinilda C Bragagnoli; Hasan S Coşkun; Antonio Cubillo Gracian; Toshimi Takano; Rachel Wong; Howard Safran; Gina M Vaccaro; Zev A Wainberg; Matthew R Silver; Huiling Xiong; Janet Hong; Julien Taieb; Yung-Jue Bang
Journal:  J Clin Oncol       Date:  2020-11-16       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.